Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence, Japan, 2023

Abstract

We assessed SARS-CoV-2 seroprevalence in Japan during July–August 2023, with a focus on 2 key age groups, 0–15 and >80 years. We estimated overall seroprevalence of 45.3% for nucleocapsid antibodies and 95.4% for spike antibodies and found notable maternally derived spike antibodies in infants 6–11 months of age (90.0%).

Keywords

• COVID-19
• SARS-CoV-2
• viruses
• respiratory infections
• zoonoses
• vaccine-preventable diseases